When people speak of today’s medicine, precision plays one of the most significant roles and people’s lives are literally dependent on it. Hence, any researches pertaining to medicine are required to meet the top standards. The issue nowadays is that any conclusions of researches can be posted online and used as a reference without being adequately checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this challenge and tried to come up with an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been founded back in 2010. The main principle of this journal is based on Altmetric scores that are used as a quality indicator. That allows both readers and authors to validate publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication. ” Oncotarget website provides a complete publications list with corresponding scores higher than 100 as well as reports mentioned above. (Misha) Blagosklonny proud to share his new approach and hopes it provides the necessary help to anyone, who has interest in oncology. “A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This article was published back in 2018 by Oncotarget and written by diversified experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study mentions that “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and provides an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage. ” The article has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that most of readers are willing to understand the very meaning of it. Based on the Altmetric website, the score relates to “how many people have been exposed to and engaged with a scholarly output. ” Likewise, the publication about melanoma, was used for citations in various news articles 69 times. In addition, it was mentioned in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their report on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot, ”. This publication has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have seen a brief overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive helpful scientific facts. Oncotarget is glad to have the ability to share with online customers this highly appreciated and top-quality information, that is trustworthy and reliable.